Clinical Trials
50 trialsNCT05564377 2026-05-27
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05554380 2026-05-22
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Suspended
NCT05554341 2026-05-14
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03907475 2026-05-13
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06846346 2026-04-28
GRACIE
UNICANCER
Phase 2 Recruiting
NCT07007559 2026-04-13
ASPEN-09-03
ALX Oncology Inc.
Phase 2 Recruiting
NCT07423078 2026-04-13
WOLF
University of Pittsburgh
Phase 2 Recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT00781612 2025-12-24
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.
Phase 2 Active not recruiting
NCT01898117 2025-11-26
Triple-B
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT06246110 2025-11-12
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Eikon Therapeutics
Phase 2 Recruiting
NCT05014815 2025-09-16
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
BeiGene
Phase 2 Completed
NCT02423603 2025-03-10
PAKT
Queen Mary University of London
Phase 2 Completed
NCT03921671 2024-05-29
RELEVENT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT01953926 2024-03-12
SUMMIT
Puma Biotechnology, Inc.
Phase 2 Terminated
NCT03841747 2024-03-12
PELICAN
Queen Mary University of London
Phase 2 Withdrawn
NCT02954055 2024-02-26
METEORA-II
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT04694183 2024-02-07
The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer
The First Hospital of Jilin University
Phase 2 Completed
NCT00993655 2023-08-28
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT04808466 2022-02-21
WUHIPEC01
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT01835236 2021-03-30
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
Swiss Cancer Institute
Phase 2 Completed
NCT03887442 2021-01-07
EXTAX
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 2 Terminated
NCT02280252 2020-11-23
Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
NYU Langone Health
Phase 2 Completed
NCT02124707 2020-08-12
Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02560038 2018-11-28
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT01852292 2018-07-24
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
Novartis
Phase 2 Terminated
NCT01009515 2017-10-18
Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT02474186 2017-08-03
Phase II Study for Solid Metastatic Tumors
NYU Langone Health
Phase 2 Completed
NCT01774851 2017-06-22
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Merrimack Pharmaceuticals
Phase 2 Terminated
NCT01108055 2017-06-09
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Stanford University
Phase 2 Completed
NCT00350025 2017-03-31
Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT02274012 2017-03-14
Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment
Columbia University
Phase 2 Withdrawn
NCT02855788 2016-08-04
Metronomic Chemotherapy in Advanced Gastric Cancer
Huashan Hospital
Phase 2 Unknown
NCT01447706 2016-05-12
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Merrimack Pharmaceuticals
Phase 2 Completed
NCT00998192 2016-03-31
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Oncolytics Biotech
Phase 2 Completed
NCT01069796 2016-03-17
Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer
ARCAGY/ GINECO GROUP
Phase 2 Terminated
NCT02051868 2015-11-04
InterAACT
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT00511459 2015-10-29
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
Amgen
Phase 2 Completed
NCT01560104 2015-10-21
A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
AbbVie
Phase 2 Completed
NCT01703910 2015-10-09
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase 2 Completed
NCT01011075 2015-07-03
6137p
New Mexico Cancer Research Alliance
Phase 2 Completed
NCT00984464 2015-04-10
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
Oncolytics Biotech
Phase 2 Completed
NCT01579578 2014-09-12
Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer
AstraZeneca
Phase 2 Terminated
NCT01971034 2014-05-16
Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure.
Instituto do Cancer do Estado de São Paulo
Phase 2 Completed
NCT00476827 2013-07-17
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Duke University
Phase 2 Terminated
NCT00100789 2012-10-01
S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00448305 2012-01-05
EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients
MediGene
Phase 2 Completed
NCT01169870 2012-01-04
Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients
National Cancer Center, Korea
Phase 2 Withdrawn
NCT00270491 2011-02-25
Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT00034346 2007-12-24
ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Amgen
Phase 2 Completed